(Ivanhoe Newswire) – An oral medication could help some patients with
inflammatory breast cancer.
Aggressive forms of inflammatory breast cancer can be difficult to treat, often
unresponsive to chemotherapy, radiation or approved medications. For patients
whose disease is resistant to anthracycline or taxane and trastuzumab treatment,
options are limited. However, a new study of the oral growth inhibitor,
lapatinib, showed promise for patients for which all other treatment options
have failed.
Patients were given 1,500 milligrams of lapatinib once daily and were followed
for two and a half years. Thirty-nine percent of patients showed a partial
response to treatment. After six months, 22 percent of patients’ disease was
progression-free. However, adverse effects were reported in 92 percent of
patients, including shortness of breath, fluid around the lungs and death.
"Lapatinib monotherapy is potentially clinically effective in heavily pretreated
patients with inflammatory breast cancer with HER2+ tumors,” study authors
wrote. “The objective response rate noted...coupled with the median duration of
response and median overall survival supports a role for lapatinib in these
patients."
SOURCE: Lancet Oncology, 2009
